November 14, 2019
Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor
Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor to Be Presented at the…
Read More
September 25, 2019
Invest in the Future of Health Biotech, European Biotech Week
Invest in the Future of Health Biotech during the European Biotech Week 2019 (Brussels) …
Read More
June 3, 2019
S.A.B Meeting in Chicago, during ASCO 2019
Scientific Advisory Board Meeting during ASCO 2019 Chicago, USA, June 3, 2019 — Genoscience…
Read More
April 17, 2019
Chaim Hurvitz, New Board of Directors Member
Chaim Hurvitz, New Board of Directors Member Chaim Hurvitz has joined Genoscience Pharma Board…
Read More
December 10, 2018
Most Innovative European Biotech SME for 2018
Most Innovative European Biotech SME for 2018 Bruxelles, Belgium, December 3, 2018 - Company…
Read More
October 5, 2018
Extension to US of GNS561 Clinical Trial
Genoscience Pharma Extends to US its Clinical Trial in Patients with Advanced Liver Cancers …
Read More
June 4, 2018
S.A.B. Meeting in Chicago, during ASCO 2018
Scientific Advisory Board Meeting during ASCO 2018 Chicago, USA, June 4, 2018 — During…
Read More
May 22, 2018
Extension to France of GN561 Clinical trial
Genoscience Pharma Extends its GNS561 Clinical Trial to France Enrollment is open for patients…
Read More
April 5, 2018
First-in-human Dosing of GNS561 in Liver Cancer Patients
First-in-human Dosing of GNS561 in Patients with Advanced Liver Cancer at the Jules Bordet Institute,…
Read More
December 6, 2017
GNS561 Gets US FDA IND Approval in Liver Cancer
Genoscience Pharma Receives FDA Approval for Phase Ib/IIa Study of GNS561 in Liver Cancer …
Read More
